Innovative Journal of Pediatrics
Volume 31 · Issue 6 · e111562

OPEN PEER REVIEW

Elosulfase Alfa Treatment in Morquio A Patients in Iran: A Before and After Study

Mohammadreza Alaei, Marjan Shakiba, Hedieh Saneifard, Ghamartaj Khanbabaee, Mohammadreza Khalilian, Asieh Mosallanejad, Saleheh Tajalli, Mojtaba Lotfi

SUBMITTED	REVISED	ACCEPTED	DOI
24 Nov 2020	23 Oct 2021	24 Oct 2021	10.5812/ijp.111562

About this report

This open peer review (OPR) report shows the public comments made on this article during peer review, by the reviewers, the associate editor and the editor-in-chief, for every revision round, together with the authors' replies. Comments appear only with the consent of the people who wrote them. Reviewers who chose to sign their report are named; the others are shown as "Referee". Comments are edited for language only, and confidential remarks to the editors are not included.

More about open peer review: brieflands.com/knowledgebase/opr

Contents

1 **Original submission** Abdulkerim Kasim Baltaci 2
2 **Revision 1** Referee 1 3
Authors' reply to reviewers 4
Reviewer and editor comments 6
3 **Revision 2** 7
Authors' reply to reviewers 8
Reviewer and editor comments 9

1 Original submission

1 comment · 16 Jun 2021

Abdulkerim Kasim Baltaci Reviewer

MINOR REVISION 16 Jun 2021

Report:
The aim of this study was to evaluate the impact of the addition of elosulfase alfa to the hospital protocol for the treatment of Iranian pediatric patients with Morquio A syndrome.
In their study, the authors reported that they achieved significant improvement after the treatment period with the addition of elosulfase alfa in patients with Morquio A syndrome.
In 2014, the use of elosulfase alfa was approved in the European Union, Canada, the United States, Australia, and Brazil for the treatment of Morquio A syndrome. Elosulfase alfa is administered intravenously once weekly at a dose of 2.0 mg/kg.
There is no consensus among reports on the beneficial effects of using elosulfase alfa in patients with Morquio A syndrome. The number of subjects in studies on the subject is higher than the number of subjects in this study.
The number of subjects in this study is limited. The study is limited only to patients with Morquio A syndrome admitted to a children's hospital in Tehran.
In this respect, this is a preliminary study. It can be considered a short article.
Authors are encouraged to use the following references in their article (PMID: 25234648, PMID: 27855521, PMID: 25200032, PMID: 27774754).
Conclusion: This article can be accepted as a short article after corrections.

2

Revision 1

AUTHORS' RESPONSE TO REVIEWERS

Authors' reply to reviewers

The next pages contain the authors' point-by-point reply to the comments of this revision round, as submitted with the revised manuscript. It is published as the authors wrote it.

Reviewers' Comments:	Reply to Reviewers
Your title should change because a noun needs to be after adjective (pediatrics)	*Title was revised*
Abstract should be more than 250 word	*Abstract was revised*
It is better not to use previous study in introduction part in details	*Introduction was revised*
In general grammatical correction should be done in all part of manuscript (for example : for evaluate, second of physical ability, and etc .....)	*Fluent English was considered*
Manuscript should be written in fluent english	*Fluent English was considered*
I reviewed the manuscript, and there was major problems in english structure from the title through the article which needs to be revised.for example: -In the title, morquio A is not a syndrome and "a" should be in capital letter all through the article. It is better to change the title to " Elosulfase Alfa treatment in Morquio A patients in Iran, a before and after study "	*Fluent English was considered*
there are lots of grammar mistakes as " fellowship of ped endocrinologist" which should be "endocrinology" in line 105	*Fluent English was considered*
in line 190, "we also had a wonderful finding" is not appropriate for a scientific journal.	*This was revised*
in line 200 " the result of our stair climbing test" was that yours or your patients??!!	*This section was revised*
In the conclusion part is walking 6 min different from 6MWT?	*Yes. This section was revised*
The p value for spirometry is not calculated for the 5 patients more than 5 years old in table 3.	*The table 3 was revised*
The aim of this presented study was to evaluate the impact of addition of elosulfase alfa to the hospital protocol for treatment of Iranian pediatrics with Morquio A syndrome.In their study, the authors reported that they achieved significant improvement after the treatment period with the addition of Elosulfase alfa in patients with Morquio A syndrome.In 2014, the use of elosulfase alfa, was approved in the European Union, Canada, the United States, Australia, and Brazil for the treatment of Morquio A syndrome. Elosulfase alfa is administered intravenously once-weekly at a dose of 2.0 mg/kg.There is no consensus among reports on the beneficial effects of using elosulfase alfa in patients with Morquio A syndrome. The number of subjects in studies on the subject is higher than the subjects used in this study.	*This section was revised*
The number of subjects used in this study is limited. The study is limited only to patients with Morquio A syndrome admitted to a children's hospital in Tehran. In this respect, this study presented is a preliminary study. It can be considered as a short article. Authors are encouraged to use the following references in their article (PMID: 25234648, PMID: 27855521, PMID: 25200032, PMID: 27774754).	*New references were considered*

2 Revision 1

1 comment · 28 Aug 2021

Referee 1 Reviewer

MINOR REVISION 28 Aug 2021

Dear author
Some corrections need to be made:
1- In different parts of the study, the number of participants is reported as 10, 17, and 16, for example, in the abstract, results, and diagram. This should be corrected.
2- In the results, mean+/_ SD should be corrected.
3- Grammatical corrections should be made, for example, to stair climbing and walking test.

3

Revision 2

AUTHORS' RESPONSE TO REVIEWERS

Authors' reply to reviewers

The next pages contain the authors' point-by-point reply to the comments of this revision round, as submitted with the revised manuscript. It is published as the authors wrote it.

Dear Editor-in-Chief of the esteemed journal Iranian Journal of Pediatrics,

With greetings and respect,

Regarding the article with code 111562 entitled Iranian Pediatric with Morquio a Syndrome Underwent Elosulfase Alfa Prescription: A Before and After Study

The corrections of the third round of review consist of the correction of the table number, which is highlighted in yellow.

With respect,

3 Revision 2

0 comments

No public comments in this round.